^
    15h
    RT4: Proof of Concept for Real-time Multicentric Monitoring of MRD by PET and ctDNA in Aggressive B-Cell Lymphomas (clinicaltrials.gov)
    P=N/A, N=129, Not yet recruiting, The Lymphoma Academic Research Organisation
    New trial • Minimal residual disease • Circulating tumor DNA
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    20h
    ECLAT: A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=0, Withdrawn, Memorial Sloan Kettering Cancer Center | N=27 --> 0 | Trial completion date: Aug 2028 --> Mar 2026 | Recruiting --> Withdrawn | Trial primary completion date: Aug 2028 --> Mar 2026
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD4 (CD4 Molecule)
    |
    lenalidomide • Epkinly (epcoritamab-bysp) • Monjuvi (tafasitamab-cxix)
    1d
    Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Gazyva (obinutuzumab) • golcadomide (CC-99282)
    2d
    A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) (clinicaltrials.gov)
    P1/2, N=85, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    golcadomide (CC-99282)
    3d
    Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders. (PubMed, Pharmacol Res)
    Aberrant B cell receptor signaling occurs in several B cell neoplasms including follicular lymphoma (treated with zanubrutinib, a BTK inhibitor), mantle cell lymphoma (acalabrutinib, pirtobrutinib, zanubrutinib), marginal zone lymphoma (zanubrutinib), chronic lymphocytic leukemia and small lymphocytic lymphoma (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib), and Waldenström macroglobulinemia (ibrutinib, zanubrutinib)...Pirtobrutinib fails to form a covalent bond and is a reversible BTK inhibitor. The FDA-approvals of rilzabrutinib and remibrutinib (2025) represent the first nononcologic authorizations for BTK antagonists.
    FDA event • Review • Journal
    |
    BTK (Bruton Tyrosine Kinase) • PLCG2 (Phospholipase C Gamma 2) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • SYK (Spleen tyrosine kinase)
    |
    Imbruvica (ibrutinib) • imatinib • cyclophosphamide • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • vincristine • prednisone • Jaypirca (pirtobrutinib) • Rhapsido (remibrutinib)
    5d
    GVHD-PTCy: Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention (clinicaltrials.gov)
    P2, N=41, Recruiting, Milton S. Hershey Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide
    5d
    A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=12, Completed, CRISPR Therapeutics | Recruiting --> Completed | N=290 --> 12 | Trial completion date: Nov 2030 --> Mar 2026 | Trial primary completion date: May 2030 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CTX131
    6d
    Single-cell sequencing reveals dynamic immune features of paraneoplastic pemphigus in a patient with follicular lymphoma. (PubMed, Front Immunol)
    The observed changes are compatible with post-treatment immune remodeling involving specific T cell responses and TCR clone expansion. This longitudinal single-cell analysis describes the immune landscape observed in a patient with FL-associated PNP and reveals dynamic features associated with treatment response, providing a resource and generating hypotheses for future study.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    6d
    Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=3, Terminated, Weill Medical College of Cornell University | N=38 --> 3 | Trial completion date: Dec 2028 --> Feb 2026 | Recruiting --> Terminated | Trial primary completion date: Dec 2026 --> Feb 2026; Low accrual
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Venclexta (venetoclax) • Tazverik (tazemetostat)
    6d
    RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas (clinicaltrials.gov)
    P1/2, N=10, Not yet recruiting, Affiliated Hospital of Nantong University
    New P1/2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    6d
    A051902: Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma (clinicaltrials.gov)
    P2, N=170, Suspended, Alliance for Clinical Trials in Oncology | Trial completion date: Jun 2026 --> May 2027 | Trial primary completion date: Jun 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    PD-1 (Programmed cell death 1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL6 (B-cell CLL/lymphoma 6) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • MME (Membrane Metalloendopeptidase)
    |
    TNFRSF8 expression
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral)
    6d
    Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | N=50 --> 23
    Enrollment closed • Enrollment change
    |
    EZH2 mutation
    |
    Tazverik (tazemetostat) • Lunsumio (mosunetuzumab-axgb)